

Søren M Bentzen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5958244/publications.pdf>

Version: 2024-02-01

533
papers

34,155
citations

2802

94
h-index

4991

167
g-index

543
all docs

543
docs citations

543
times ranked

23564
citing authors

#	ARTICLE	IF	CITATIONS
1	An Estimate of Local Failure in the TARGIT-A Trial of Pre-pathology Intraoperative Radiation Therapy for Early Breast Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2023, 115, 73-76.	0.8	7
2	Radiation-Induced Toxicity Risks in Photon Versus Proton Therapy for Synchronous Bilateral Breast Cancer. <i>International Journal of Particle Therapy</i> , 2022, 8, 1-13.	1.8	0
3	Proton vs photon radiation therapy for glioblastoma: Maximizing information from trial. <i>Neuro-Oncology</i> , 2022, 24, 849-850.	1.2	3
4	Phase I Clinical Trial of DNA Methyltransferase Inhibitor Decitabine and PARP Inhibitor Talazoparib Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2022, 28, 1313-1322.	7.0	16
5	Identifying Psychosocial Needs of Patients With Cancer Undergoing Curative Radiation Therapy in an Inner-City Academic Center to Address Racial Disparities. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 114, 185-194.	0.8	5
6	Methodological Comparison of Mapping the Expanded Prostate Cancer Index Composite to EuroQoL-5D-3L Using Cross-Sectional and Longitudinal Data: Secondary Analysis of NRG/RTOG 0415. <i>JCO Clinical Cancer Informatics</i> , 2022, , .	2.1	0
7	Organs at Risk Considerations for Thoracic Stereotactic Body Radiation Therapy: What Is Safe for Lung Parenchyma?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 172-187.	0.8	52
8	Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes. <i>Neuro-Oncology</i> , 2021, 23, 112-121.	1.2	53
9	Persistence of Late Substantial Patient-Reported Symptoms (LAPERS) After Radiochemotherapy Including Image Guided Adaptive Brachytherapy for Locally Advanced Cervical Cancer: A Report From the EMBRACE Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 161-173.	0.8	16
10	Antileukemic efficacy of a potent artemisinin combined with sorafenib and venetoclax. <i>Blood Advances</i> , 2021, 5, 711-724.	5.2	10
11	Soluble Sema4D in Plasma of Head and Neck Squamous Cell Carcinoma Patients Is Associated With Underlying Non-Inflamed Tumor Profile. <i>Frontiers in Immunology</i> , 2021, 12, 596646.	4.8	11
12	Primary Hypothyroidism in Childhood Cancer Survivors Treated With Radiation Therapy: A PENTEC Comprehensive Review. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, , .	0.8	12
13	Pediatric Normal Tissue Effects in the Clinic (PENTEC): An International Collaboration to Assess Normal Tissue Radiation Dose-Volume-Response Relationships for Children With Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, , .	0.8	10
14	Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415. <i>PLoS ONE</i> , 2021, 16, e0249123.	2.5	4
15	Adherence to Guideline-Concordant Care and Its Effect on Survival in Black Patients with Head and Neck Cancers: A SEER-Medicare Analysis. <i>Oncologist</i> , 2021, 26, 579-587.	3.7	8
16	Intratumor heterogeneity is biomarker specific and challenges the association with heterogeneity in multimodal functional imaging in head and neck squamous cell carcinoma. <i>European Journal of Radiology</i> , 2021, 139, 109668.	2.6	4
17	Brief Report: Herpes Simplex Virus Type-2 Shedding and Genital Ulcers During Early HIV in Zimbabwean Women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 87, 789-793.	2.1	0
18	Metabolic heterogeneous zone assessed by ¹⁸ F-FDG-PET is predictive of postablation mortality in patients with ventricular tachycardia. <i>Journal of Cardiovascular Electrophysiology</i> , 2021, 32, 2238-2245.	1.7	1

#	ARTICLE	IF	CITATIONS
19	C5a Activates a Pro-Inflammatory Gene Expression Profile in Human Gaucher iPSC-Derived Macrophages. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9912.	4.1	14
20	Outcome-based multiobjective optimization of lymphoma radiation therapy plans. <i>British Journal of Radiology</i> , 2021, 94, 20210303.	2.2	6
21	Radiation Dose Escalation for Early Prostate Cancer: Reigniting the FLAME?. <i>Journal of Clinical Oncology</i> , 2021, 39, 3085-3086.	1.6	4
22	MYC DNA Methylation in Prostate Tumor Tissue is Associated with Gleason Score. <i>Genes</i> , 2021, 12, 12.	2.4	6
23	Simulation of an HDR "Boost" with Stereotactic Proton versus Photon Therapy in Prostate Cancer: A Dosimetric Feasibility Study. <i>International Journal of Particle Therapy</i> , 2021, 7, 11-23.	1.8	0
24	Evaluating the Jaccard Similarity Index as a Persistence Measure of Multiple Anal Human Papillomavirus among Nigerian Men Who Have Sex with Men. <i>Sexually Transmitted Diseases</i> , 2021, Publish Ahead of Print, .	1.7	0
25	Total Body Irradiation in Haematopoietic Stem Cell Transplantation for Paediatric Acute Lymphoblastic Leukaemia: Review of the Literature and Future Directions. <i>Frontiers in Pediatrics</i> , 2021, 9, 774348.	1.9	15
26	Aspartate \hat{I}^2 -Hydroxylase (ASPH) Expression in Acute Myeloid Leukemia: A Potential Novel Therapeutic Target. <i>Frontiers in Oncology</i> , 2021, 11, 783744.	2.8	2
27	Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy. <i>Journal of the National Cancer Institute</i> , 2020, 112, 179-190.	6.3	71
28	Late, Persistent, Substantial, Treatment-Related Symptoms After Radiation Therapy (LAPERS): A New Method for Longitudinal Analysis of Late Morbidity" Applied in the EMBRACE Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 300-309.	0.8	22
29	Insurance Status is an Independent Predictor of Overall Survival in Patients With Stage III Non"small-cell Lung Cancer Treated With Curative Intent. <i>Clinical Lung Cancer</i> , 2020, 21, e130-e141.	2.6	8
30	Multiple Testing, Cut-Point Optimization, and Signs of Publication Bias in Prognostic FDG"PET Imaging Studies of Head and Neck and Lung Cancer: A Review and Meta-Analysis. <i>Diagnostics</i> , 2020, 10, 1030.	2.6	2
31	Targeted Intraoperative Radiotherapy for Early Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 1636.	7.1	8
32	In Reply to Berk and Alfonso. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 834-835.	0.8	1
33	Radiation Fractionation Schedules Published During the COVID-19 Pandemic: A Systematic Review of the Quality of Evidence and Recommendations for Future Development. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 379-389.	0.8	47
34	In Regard to Thomson et al.. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 853-854.	0.8	2
35	Does multiparametric imaging with 18F-FDG-PET/MRI capture spatial variation in immunohistochemical cancer biomarkers in head and neck squamous cell carcinoma?. <i>British Journal of Cancer</i> , 2020, 123, 46-53.	6.4	13
36	Multiple HPV infections among men who have sex with men engaged in anal cancer screening in Abuja, Nigeria. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2020, 10, 100200.	4.5	12

#	ARTICLE	IF	CITATIONS
37	Biological optimization for mediastinal lymphoma radiotherapy – a preliminary study. <i>Acta Oncologica</i> , 2020, 59, 879-887.	1.8	8
38	Comparison of High-Dose Cytarabine, Mitoxantrone, and Pegaspargase (HAM-pegA) to High-Dose Cytarabine, Mitoxantrone, Cladribine, and Filgrastim (CLAG-M) as First-Line Salvage Cytotoxic Chemotherapy for Relapsed/Refractory Acute Myeloid Leukemia. <i>Journal of Clinical Medicine</i> , 2020, 9, 536.	2.4	11
39	Diminishing Returns From Ultrahypofractionated Radiation Therapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 299-304.	0.8	37
40	Satisfaction with high-resolution anoscopy for anal cancer screening among men who have sex with men: a cross-sectional survey in Abuja, Nigeria. <i>BMC Cancer</i> , 2020, 20, 98.	2.6	3
41	Radiation dose-painting with protons vs. photons for head-and-neck cancer. <i>Acta Oncologica</i> , 2020, 59, 525-533.	1.8	11
42	Circulating cell free DNA during definitive chemo-radiotherapy in non-small cell lung cancer patients – initial observations. <i>PLoS ONE</i> , 2020, 15, e0231884.	2.5	11
43	Patient reported outcomes following proton pencil beam scanning vs. passive scatter/uniform scanning for localized prostate cancer: Secondary analysis of PCG 001-09. <i>Clinical and Translational Radiation Oncology</i> , 2020, 22, 50-54.	1.7	5
44	Harnessing data science to advance radiation oncology. <i>Molecular Oncology</i> , 2020, 14, 1514-1528.	4.6	16
45	Understanding High-Dose, Ultra-High Dose Rate, and Spatially Fractionated Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 766-778.	0.8	70
46	Title is missing!. , 2020, 15, e0231884.		0
47	Title is missing!. , 2020, 15, e0231884.		0
48	Title is missing!. , 2020, 15, e0231884.		0
49	Title is missing!. , 2020, 15, e0231884.		0
50	Implementation of and Early Outcomes From Anal Cancer Screening at a Community-Engaged Health Care Facility Providing Care to Nigerian Men Who Have Sex With Men. <i>Journal of Global Oncology</i> , 2019, 5, 1-11.	0.5	9
51	Consensus Report From the Miami Liver Proton Therapy Conference. <i>Frontiers in Oncology</i> , 2019, 9, 457.	2.8	15
52	PV-0368 Persistence of late substantial patient reported symptoms (LAPERS): A report from the EMBRACE study. <i>Radiotherapy and Oncology</i> , 2019, 133, S183-S184.	0.6	1
53	EP-1368 Circulating cell free DNA during chemoradiotherapy in non-small cell lung cancer patients. <i>Radiotherapy and Oncology</i> , 2019, 133, S747-S748.	0.6	0
54	Proton beam therapy delivered using pencil beam scanning vs. passive scattering/uniform scanning for localized prostate cancer: Comparative toxicity analysis of PCG 001-09. <i>Clinical and Translational Radiation Oncology</i> , 2019, 19, 80-86.	1.7	13

#	ARTICLE	IF	CITATIONS
55	Hypothyroidism (HT) after Radiotherapy (RT) in Children: Initial Results of Thyroid Gland Dose-Response Relationship from the Pediatric Normal Tissue Effects in the Clinic (PENTEC) Initiative. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, S81.	0.8	1
56	Reporting of Late Morbidity After Radiation Therapy in Large Prospective Studies: A Descriptive Review of the Current Status. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 957-967.	0.8	17
57	The Implications of Genetic Testing on Radiation Therapy Decisions: A Guide for Radiation Oncologists. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 698-712.	0.8	69
58	In Reply to Tommasino et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 677-678.	0.8	0
59	Pediatric Normal Tissue Effects in the Clinic (PENTEC): An International Collaboration to Analyse Normal Tissue Radiation Dose-Volume Response Relationships for Paediatric Cancer Patients. <i>Clinical Oncology</i> , 2019, 31, 199-207.	1.4	58
60	Patterns of Care and Survival in Stage III NSCLC Among Black and Latino Patients Compared With White Patients. <i>Clinical Lung Cancer</i> , 2019, 20, 248-257.e4.	2.6	12
61	Quantification of Acute Skin Toxicities in Patients With Breast Cancer Undergoing Adjuvant Proton versus Photon Radiation Therapy: A Single Institutional Experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 1084-1090.	0.8	47
62	Downstream Effect of a Proton Treatment Center on an Academic Medical Center. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 756-764.	0.8	2
63	Inverse radiotherapy planning based on bioeffect modelling for locally advanced left-sided breast cancer. <i>Radiotherapy and Oncology</i> , 2019, 136, 9-14.	0.6	4
64	Assessment of Machine Learning vs Standard Prediction Rules for Predicting Hospital Readmissions. <i>JAMA Network Open</i> , 2019, 2, e190348.	5.9	71
65	Intratumor genetic heterogeneity in squamous cell carcinoma of the oral cavity. <i>Head and Neck</i> , 2019, 41, 2514-2524.	2.0	22
66	NK cell expression of Tim-3: First impressions matter. <i>Immunobiology</i> , 2019, 224, 362-370.	1.9	38
67	Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma. <i>British Journal of Cancer</i> , 2019, 120, 1003-1006.	6.4	109
68	Equipotent doses of daunorubicin and idarubicin for AML: a meta-analysis of clinical trials versus in vitro estimation. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 1105-1112.	2.3	12
69	Trends in utilization of hypofractionated whole breast irradiation (HF-WBI) in triple negative breast cancer (TNBC): a national cancer database (NCDB) analysis. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 473-478.	2.5	2
70	On the relation between improved loco-regional control and disease-free survival in head-and-neck cancer. <i>Acta Oncologica</i> , 2019, 58, 390-392.	1.8	1
71	Anal Microbial Patterns and Oncogenic Human Papillomavirus in a Pilot Study of Nigerian Men Who Have Sex with Men at Risk for or Living with HIV. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 267-275.	1.1	7
72	Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) after CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CAR-T) for Large B-Cell Lymphoma: Predictive Biomarkers and Clinical Outcomes. <i>Blood</i> , 2019, 134, 3239-3239.	1.4	4

#	ARTICLE	IF	CITATIONS
73	Incorporating NTCP into Randomized Trials of Proton Versus Photon Therapy. <i>International Journal of Particle Therapy</i> , 2019, 5, 24-32.	1.8	2
74	PD-L1, B7-H3, and PD-1 expression in immunocompetent vs. immunosuppressed patients with cutaneous squamous cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 805-814.	4.2	41
75	Dose Response and Fractionation Sensitivity of Prostate Cancer After External Beam Radiation Therapy: A Meta-analysis of Randomized Trials. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 858-865.	0.8	62
76	Postmarket Safety Outcomes for New Molecular Entity (NME) Drugs Approved by the Food and Drug Administration Between 2002 and 2014. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 390-400.	4.7	31
77	A Competing Risk Model of First Failure Site after Definitive Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 559-567.	1.1	16
78	Asparaginase <i>Erwinia chrysanthemi</i> effectively depletes plasma glutamine in adult patients with relapsed/refractory acute myeloid leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 217-222.	2.3	36
79	Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline. <i>Journal of Clinical Oncology</i> , 2018, 36, 3411-3430.	1.6	118
80	The Downstream Effect of a Proton Therapy Center on an Academic Medical Center. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, e427-e428.	0.8	0
81	Patient-Reported Outcomes (PROs) Comparing Pencil Beam Scanning (PBS) and Double Scatter/Uniform Scanning Proton Beam Therapy for Localized Prostate Cancer (PC): Analysis of PCG 001-09. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, S34-S35.	0.8	1
82	Preliminary toxicity report comparing pencil beam scanning (PBS) to double scatter/uniform scanning proton beam therapy for localized prostate cancer (PC): Analysis of PCG 001-09. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, S164-S165.	0.8	0
83	Definitive radiation with concurrent cetuximab vs. radiation with or without concurrent cytotoxic chemotherapy in older patients with squamous cell carcinoma of the head and neck: Analysis of the SEER-medicare linked database. <i>Oral Oncology</i> , 2018, 86, 132-140.	1.5	20
84	Individualized estimates of overall survival in radiation therapy plan optimization – A concept study. <i>Medical Physics</i> , 2018, 45, 5332-5342.	3.0	6
85	Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO, and AUA Evidence-Based Guideline. <i>Practical Radiation Oncology</i> , 2018, 8, 354-360.	2.1	151
86	Feasibility of concomitant cisplatin with hypofractionated radiotherapy for locally advanced head and neck squamous cell carcinoma. <i>BMC Cancer</i> , 2018, 18, 1026.	2.6	22
87	Outcomes of a Community-based Breast Cancer Screening Program in Baltimore City. <i>Journal of Health Care for the Poor and Underserved</i> , 2018, 29, 898-913.	0.8	1
88	Retrospective estimation of heart and lung doses in pediatric patients treated with spinal irradiation. <i>Radiotherapy and Oncology</i> , 2018, 128, 209-213.	0.6	3
89	Radiobiology of Proton Therapy: Results of an international expert workshop. <i>Radiotherapy and Oncology</i> , 2018, 128, 56-67.	0.6	85
90	Case-control study of PD-1, PD-L1 and B7-H3 expression in lung cancer patients with and without human immunodeficiency virus (HIV) infection. <i>Lung Cancer</i> , 2018, 123, 87-90.	2.0	11

#	ARTICLE	IF	CITATIONS
91	Editorial: Data Based Radiation Oncology Design of Clinical Trials. <i>Frontiers in Oncology</i> , 2018, 8, 34.	2.8	0
92	Prognostic models for patients with brain metastases after stereotactic radiosurgery with or without whole brain radiotherapy: a validation study. <i>Journal of Neuro-Oncology</i> , 2018, 140, 341-349.	2.9	12
93	A clinical prognostic model compared to the newly adopted UICC staging in an independent validation cohort of P16 negative/positive head and neck cancer patients. <i>Oral Oncology</i> , 2018, 81, 52-60.	1.5	8
94	Aspartate Beta-Hydroxylase (ASPH) As a Novel Therapeutic Target in Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 5273-5273.	1.4	1
95	Repeatability of FDG PET/CT metrics assessed in free breathing and deep inspiration breath hold in lung cancer patients. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 8, 127-136.	1.0	2
96	Obesity is associated with long-term improved survival in definitively treated locally advanced non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2017, 104, 52-57.	2.0	61
97	Effect of reduction mammoplasty on acute radiation side effects and use of lumpectomy cavity boosts. <i>Practical Radiation Oncology</i> , 2017, 7, e299-e308.	2.1	1
98	Genotyping of high-risk anal human papillomavirus (HPV): ion torrent-next generation sequencing vs. linear array. <i>Virology Journal</i> , 2017, 14, 112.	3.4	12
99	Neutrophil-Lymphocyte Ratio Is a Prognostic Marker in Patients with Locally Advanced (Stage IIIA and) Tj ETQq1 1 0,784314 rgBT /Ove	3.7	82
100	(S001) Regional Nodal Irradiation in Elderly Node Positive Women: A Patterns of Care Study on Changes in Utilization Over a Decade. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, E1.	0.8	0
101	Rectal microbiota among HIV-uninfected, untreated HIV, and treated HIV-infected in Nigeria. <i>Aids</i> , 2017, 31, 857-862.	2.2	46
102	Joint Estimation of Cardiac Toxicity and Recurrence Risks After Comprehensive Nodal Photon Versus Proton Therapy for Breast Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 754-761.	0.8	46
103	A failure-type specific risk prediction tool for selection of head-and-neck cancer patients for experimental treatments. <i>Oral Oncology</i> , 2017, 74, 77-82.	1.5	10
104	Utilization of Hypofractionated Whole Breast Radiation Therapy in Patients Receiving Chemotherapy (2004-2013): A National Cancer Database Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, E394.	0.8	0
105	Dosimetric Comparison of Patient Alignment Techniques in Pencil Beam Scanning Proton Therapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, E714.	0.8	0
106	Effect of PTV and Collimator Margins on Tumor Control for Patients with Stage III Non-small Cell Lung Cancer in NRG Oncology RTOG-0617. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, S181-S182.	0.8	1
107	Lack of Consensus Guideline Driven Approach for Utilization of Accelerated Partial Breast Irradiation in the ASTRO Cautionary Group: A National Cancer Database Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, E7-E8.	0.8	0
108	The Initial Clinical Experience of a Novel Breast Specific Stereotactic Radiosurgery Device. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, E14-E15.	0.8	1

#	ARTICLE	IF	CITATIONS
109	Trends in Utilization of Hypofractionated Whole Breast Irradiation in Triple Negative Breast Cancer: A National Cancer Database Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, E43-E44.	0.8	1
110	Immunohistochemical and molecular imaging biomarker signature for the prediction of failure site after chemoradiation for head and neck squamous cell carcinoma. <i>Acta Oncologica</i> , 2017, 56, 1562-1570.	1.8	9
111	Recombinant human IgG1 based Fc multimers, with limited FcR binding capacity, can effectively inhibit complement-mediated disease. <i>Journal of Autoimmunity</i> , 2017, 84, 97-108.	6.5	17
112	PV-0509: Failure type specific prognostic model for selection of HNSCC patients for experimental treatments. <i>Radiotherapy and Oncology</i> , 2017, 123, S268-S269.	0.6	0
113	Factors Influencing Management and Outcome in Patients with Occult Breast Cancer with Axillary Lymph Node Involvement: Analysis of the National Cancer Database. <i>Annals of Surgical Oncology</i> , 2017, 24, 2907-2914.	1.5	30
114	Expansion of Treatment for Hepatitis C Virus Infection by Task Shifting to Community-Based Nonspecialist Providers. <i>Annals of Internal Medicine</i> , 2017, 167, 311.	3.9	192
115	Clinical outcomes of black vs. non-black patients with locally advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2017, 114, 44-49.	2.0	6
116	Oncological outcomes from trimodality therapy receiving definitive doses of neoadjuvant chemoradiation (60 Gy) and factors influencing consideration for surgery in stage III non-small cell lung cancer. <i>Advances in Radiation Oncology</i> , 2017, 2, 259-269.	1.2	16
117	Multi-institutional external validation of a novel glioblastoma prognostic nomogram incorporating MGMT methylation. <i>Journal of Neuro-Oncology</i> , 2017, 134, 331-338.	2.9	21
118	Increasing utilization of regional nodal irradiation in elderly node-positive women and declining emphasis on demographic factors. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 669-676.	2.5	3
119	Study design and rationale for ELPIS: A phase I/IIb randomized pilot study of allogeneic human mesenchymal stem cell injection in patients with hypoplastic left heart syndrome. <i>American Heart Journal</i> , 2017, 192, 48-56.	2.7	38
120	Establishing Evidence-Based Indications for Proton Therapy: An Overview of Current Clinical Trials. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 228-235.	0.8	61
121	Utilization of hypofractionated whole-breast radiation therapy in patients receiving chemotherapy: a National Cancer Database analysis. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 445-453.	2.5	10
122	Data-Based Radiation Oncology: Design of Clinical Trials in the Toxicity Biomarkers Era. <i>Frontiers in Oncology</i> , 2017, 7, 83.	2.8	36
123	Effect of tumor dose, volume and overall treatment time on local control after radiochemotherapy including MRI guided brachytherapy of locally advanced cervical cancer. <i>Radiotherapy and Oncology</i> , 2016, 120, 441-446.	0.6	252
124	Optimal design and patient selection for interventional trials using radiogenomic biomarkers: A REQUITE and Radiogenomics consortium statement. <i>Radiotherapy and Oncology</i> , 2016, 121, 440-446.	0.6	15
125	Phase I trial of 18F-Fludeoxyglucose based radiation dose painting with concomitant cisplatin in head and neck cancer. <i>Radiotherapy and Oncology</i> , 2016, 120, 76-80.	0.6	55
126	Prognostic Value of 18-Fluorodeoxyglucose in Independent Training and Validation Sets of Patients With HNSCC Largely Explained by Association With Tumor Volume. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 921.	0.8	0

#	ARTICLE	IF	CITATIONS
127	Patterns of Recurrence in Patients With Locally Advanced Non-Small Cell Lung Cancer (LANSCLC) Treated With Concurrent Chemoradiation (CRT) Followed by Surgery. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, E452.	0.8	0
128	Prolongation of overall treatment time as a cause of treatment failure in early breast cancer: An analysis of the UK START (Standardisation of Breast Radiotherapy) trials of radiotherapy fractionation. <i>Radiotherapy and Oncology</i> , 2016, 121, 420-423.	0.6	36
129	Multi-institutional Validation of a Novel Glioblastoma Prognostic Nomogram Incorporating MGMT Methylation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, S182.	0.8	0
130	Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents – A Potential Therapy for Cancer. <i>Cancer Cell</i> , 2016, 30, 637-650.	16.8	151
131	Meta-analysis of Genome Wide Association Studies Identifies Genetic Markers of Late Toxicity Following Radiotherapy for Prostate Cancer. <i>EBioMedicine</i> , 2016, 10, 150-163.	6.1	69
132	Pathophysiological mechanisms underlying phenotypic differences in pulmonary radioresponse. <i>Scientific Reports</i> , 2016, 6, 36579.	3.3	18
133	Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients. <i>Radiotherapy and Oncology</i> , 2016, 121, 431-439.	0.6	98
134	Overall Survival After Endoscopic Surgery Versus Radiation as the Initial Treatment in Oropharyngeal Squamous Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 892-893.	0.8	0
135	Dose–effect relationship and risk factors for vaginal stenosis after definitive radio(chemo)therapy with image-guided brachytherapy for locally advanced cervical cancer in the EMBRACE study. <i>Radiotherapy and Oncology</i> , 2016, 118, 160-166.	0.6	153
136	Early lesion-specific 18F-FDG PET response to chemotherapy predicts time to lesion progression in locally advanced non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2016, 118, 460-464.	0.6	11
137	Radiation oncology in the era of precision medicine. <i>Nature Reviews Cancer</i> , 2016, 16, 234-249.	28.4	636
138	Radiation Lumpectomy Boost and Acute Treatment Toxicities in Patients With or Without Reduction Mammoplasty as Part of Breast Conserving Treatment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, E26.	0.8	0
139	Impact of a Contralateral Tumor Nodule on Survival in Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1608-1615.	1.1	3
140	Prognostic value of 18F-fludeoxyglucose uptake in 287 patients with head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2015, 37, 1274-1281.	2.0	18
141	Global and Regional Myocardial Innervation Before and After Ablation of Drug-Refractory Ventricular Tachycardia Assessed with ¹²³ I-MIBG. <i>Journal of Nuclear Medicine</i> , 2015, 56, 52S-58S.	5.0	20
142	In Reply to Boon et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 456-457.	0.8	0
143	Gaucher Disease-Induced Pluripotent Stem Cells Display Decreased Erythroid Potential and Aberrant Myelopoiesis. <i>Stem Cells Translational Medicine</i> , 2015, 4, 878-886.	3.3	24
144	In Regard to Vaidya et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 954-955.	0.8	4

#	ARTICLE	IF	CITATIONS
145	Molecular Imaging Biomarkers of Resistance to Radiation Therapy for Spontaneous Nasal Tumors in Canines. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 787-795.	0.8	19
146	Spatio-temporal stability of pre-treatment 18F-Fludeoxyglucose uptake in head and neck squamous cell carcinomas sufficient for dose painting. <i>Acta OncolĂgica</i> , 2015, 54, 1416-1422.	1.8	14
147	Immunohistochemical biomarkers and FDG uptake on PET/CT in head and neck squamous cell carcinoma. <i>Acta OncolĂgica</i> , 2015, 54, 1408-1415.	1.8	26
148	External validation of a normal tissue complication probability model for radiation-induced hypothyroidism in an independent cohort. <i>Acta OncolĂgica</i> , 2015, 54, 1301-1309.	1.8	24
149	Changes in pulmonary function after definitive radiotherapy for NSCLC. <i>Radiotherapy and Oncology</i> , 2015, 117, 23-28.	0.6	10
150	Clinical Outcomes for Esophageal Cancer Patients Treated With Intensity Modulated Radiation Therapy Compared to 3-D Conformal Radiation Therapy: An Analysis of the National Cancer Data Base. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, E165-E166.	0.8	0
151	In Regard to Vaidya et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 958-959.	0.8	1
152	In Reply to Yamazaki etĂal. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 245-246.	0.8	0
153	Dose-response of acute urinary toxicity of long-course preoperative chemoradiotherapy for rectal cancer. <i>Acta OncolĂgica</i> , 2015, 54, 179-186.	1.8	25
154	Radiogenomics: the search for genetic predictors of radiotherapy response. <i>Future Oncology</i> , 2014, 10, 2391-2406.	2.4	63
155	Prescribing and evaluating target dose in dose-painting treatment plans. <i>Acta OncolĂgica</i> , 2014, 53, 1251-1256.	1.8	9
156	Does Routine Clinical Practice Reproduce the Outcome of Large Prospective Trials? The Analysis of Institutional Database on Patients with Limited-Disease Small-Cell Lung Cancer. <i>Cancer Investigation</i> , 2014, 32, 1-7.	1.3	6
157	Cancer Risk from Bone Morphogenetic Protein Exposure in Spinal Arthrodesis. <i>Journal of Bone and Joint Surgery - Series A</i> , 2014, 96, 1417-1422.	3.0	75
158	Optimizing the radiation therapy dose prescription for pediatric medulloblastoma: Minimizing the life years lost attributable to failure to control the disease and late complication risk. <i>Acta OncolĂgica</i> , 2014, 53, 462-470.	1.8	18
159	Towards individualized dose constraints: Adjusting the QUANTEC radiation pneumonitis model for clinical risk factors. <i>Acta OncolĂgica</i> , 2014, 53, 605-612.	1.8	61
160	Interactive Decision-Support Tool for Risk-Based Radiation Therapy Plan Comparison for Hodgkin Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 433-445.	0.8	34
161	Single institution experience treating 104 vestibular schwannomas with fractionated stereotactic radiation therapy or stereotactic radiosurgery. <i>Journal of Neuro-Oncology</i> , 2014, 116, 187-193.	2.9	62
162	Hippocampal sparing radiotherapy for pediatric medulloblastoma: impact of treatment margins and treatment technique. <i>Neuro-Oncology</i> , 2014, 16, 594-602.	1.2	36

#	ARTICLE	IF	CITATIONS
163	STROGAR â€“ STrengthening the Reporting Of Genetic Association studies in Radiogenomics. Radiotherapy and Oncology, 2014, 110, 182-188.	0.6	59
164	A Toast to the Silver Anniversary of Clinical Oncology: A Quarter of a Century of Advances in Evidence-based Radiation Dose Fractionation. Clinical Oncology, 2014, 26, 599-601.	1.4	4
165	Possession of the ATM Codon 1853 SNP is Associated With an Increased Risk for Radiation-Induced Toxicity. International Journal of Radiation Oncology Biology Physics, 2014, 90, S148-S149.	0.8	0
166	Hypofractionated Radiation Therapy for Prostate Cancer: More Food for Thought From Recent Trial. Journal of Clinical Oncology, 2014, 32, 1852-1853.	1.6	3
167	Temporal Stability and Reproducibility of FDG-PETâ€™Based Dose Painting Targets in Head and Neck Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 90, S514-S515.	0.8	0
168	Radiogenomics: Radiobiology Enters the Era of Big Data and Team Science. International Journal of Radiation Oncology Biology Physics, 2014, 89, 709-713.	0.8	99
169	Randomized Trial of Hyperfractionation Versus Conventional Fractionation in T2 Squamous Cell Carcinoma of the Vocal Cord (RTOG 9512). International Journal of Radiation Oncology Biology Physics, 2014, 89, 958-963.	0.8	77
170	Recurrences after intensity modulated radiotherapy for head and neck squamous cell carcinoma more likely to originate from regions with high baseline [18F]-FDG uptake. Radiotherapy and Oncology, 2014, 111, 360-365.	0.6	102
171	Long-Term Results of a Randomized Trial in Locally Advanced Rectal Cancer: No Benefit From Adding a Brachytherapy Boost. International Journal of Radiation Oncology Biology Physics, 2014, 90, 110-118.	0.8	46
172	Radiotherapy for breast cancer, the TARGIT-A trial. Lancet, The, 2014, 383, 1716-1717.	13.7	32
173	A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicity. Radiotherapy and Oncology, 2014, 111, 178-185.	0.6	128
174	Locoregional Control of Non-Small Cell Lung Cancer in Relation to Automated Early Assessment of Tumor Regression on Cone Beam Computed Tomography. International Journal of Radiation Oncology Biology Physics, 2014, 89, 916-923.	0.8	62
175	Comparison of Radiation-Induced Normal Lung Tissue Density Changes for Patients From Multiple Institutions Receiving Conventional or Hypofractionated Treatments. International Journal of Radiation Oncology Biology Physics, 2014, 89, 626-632.	0.8	16
176	Equieffective dose and bioeffect modeling â€“ In reply to Dr. Fowler. Radiotherapy and Oncology, 2013, 108, 355.	0.6	0
177	Modern Hypofractionation Schedules for Tangential Whole Breast Irradiation Decrease the Fraction Size-corrected Dose to the Heart. Clinical Oncology, 2013, 25, 147-152.	1.4	57
178	Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro-Oncology, 2013, 15, 1429-1437.	1.2	746
179	Time evolution of regional CT density changes in normal lung after IMRT for NSCLC. Radiotherapy and Oncology, 2013, 109, 89-94.	0.6	45
180	Dose-Limiting Toxicity After Hypofractionated Dose-Escalated Radiotherapy in Nonâ€™Small-Cell Lung Cancer. Journal of Clinical Oncology, 2013, 31, 4343-4348.	1.6	132

#	ARTICLE	IF	CITATIONS
181	Meta-analysis of the Alpha/Beta Ratio for Prostate Cancer in the Presence of an Overall Time Factor: Bad News, Good News, or No News?. International Journal of Radiation Oncology Biology Physics, 2013, 85, 89-94.	0.8	179
182	Radiation Dose-Response Model for Locally Advanced Rectal Cancer After Preoperative Chemoradiation Therapy. International Journal of Radiation Oncology Biology Physics, 2013, 85, 74-80.	0.8	219
183	Modeling Freedom From Progression for Standard-Risk Medulloblastoma: A Mathematical Tumor Control Model With Multiple Modes of Failure. International Journal of Radiation Oncology Biology Physics, 2013, 87, 422-429.	0.8	5
184	Hypothyroidism after primary radiotherapy for head and neck squamous cell carcinoma: Normal tissue complication probability modeling with latent time correction. Radiotherapy and Oncology, 2013, 109, 317-322.	0.6	54
185	In Reply to Arcangeli et al. International Journal of Radiation Oncology Biology Physics, 2013, 85, 898-899.	0.8	0
186	Risk of Cerebrovascular Events in Elderly Patients After Radiation Therapy Versus Surgery for Early-Stage Glottic Cancer. International Journal of Radiation Oncology Biology Physics, 2013, 87, 290-296.	0.8	32
187	Locoregional Recurrence Following Accelerated Partial Breast Irradiation for Early-Stage Invasive Breast Cancer: Significance of Estrogen Receptor Status and Other Pathological Variables. Annals of Surgical Oncology, 2013, 20, 3446-3452.	1.5	15
188	Prevalence of ATM Sequence Variants in Northern Plains American Indian Cancer Patients. Frontiers in Oncology, 2013, 3, 318.	2.8	5
189	NCIâ€™s RTOG Translational Program Strategic Guidelines for the Early-Stage Development of Radiosensitizers. Journal of the National Cancer Institute, 2013, 105, 11-24.	6.3	60
190	Failure-probability driven dose painting. Medical Physics, 2013, 40, 081717.	3.0	26
191	SU-E-T-167: QA of Dose-Painting Plans: Risk of Overdosage in the High-Dose Regions?. Medical Physics, 2013, 40, 242-242.	3.0	0
192	TU-C-WAB-01: Accuracy Requirements and Uncertainty Considerations in Radiation Therapy. Medical Physics, 2013, 40, 433-433.	3.0	0
193	TH-A-WAB-11: A Novel Method to Determine Alpha/beta for Irradiated Normal Lung Tissue Using Computed Tomography Scans. Medical Physics, 2013, 40, 522-522.	3.0	0
194	Estimated clinical benefit of protecting neurogenesis in the developing brain during radiation therapy for pediatric medulloblastoma. Neuro-Oncology, 2012, 14, 882-889.	1.2	69
195	Elevation of Prostaglandin E ₂ in Lung Cancer Patients with Digital Clubbing. Journal of Thoracic Oncology, 2012, 7, 1877-1878.	1.1	14
196	Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study. Lancet Oncology, The, 2012, 13, 65-77.	10.7	202
197	Phase I Trial of Pelvic Nodal Dose Escalation With Hypofractionated IMRT for High-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 82, 184-190.	0.8	54
198	Standardized Total Average Toxicity Score: A Scale- and Grade-Independent Measure of Late Radiotherapy Toxicity to Facilitate Pooling of Data From Different Studies. International Journal of Radiation Oncology Biology Physics, 2012, 82, 1065-1074.	0.8	63

#	ARTICLE	IF	CITATIONS
199	Redesigning Radiotherapy Quality Assurance: Opportunities to Develop an Efficient, Evidence-Based System to Support Clinical Trials Report of the National Cancer Institute Work Group on Radiotherapy Quality Assurance. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 782-790.	0.8	62
200	Severe Late Toxicities Following Concomitant Chemoradiotherapy Compared to Radiotherapy Alone in Cervical Cancer: An Inter-era Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, 973-982.	0.8	80
201	Bioeffect modeling and equieffective dose concepts in radiation oncology – Terminology, quantities and units. <i>Radiotherapy and Oncology</i> , 2012, 105, 266-268.	0.6	185
202	Conducting radiogenomic research – Do not forget careful consideration of the clinical data. <i>Radiotherapy and Oncology</i> , 2012, 105, 337-340.	0.6	28
203	Spatially resolved regression analysis of pre-treatment FDG, FLT and Cu-ATSM PET from post-treatment FDG PET: An exploratory study. <i>Radiotherapy and Oncology</i> , 2012, 105, 41-48.	0.6	18
204	Individual patient data meta-analysis shows no association between the SNP rs1800469 in TGFB and late radiotherapy toxicity. <i>Radiotherapy and Oncology</i> , 2012, 105, 289-295.	0.6	65
205	Is high-dose stereotactic body radiotherapy (SBRT) for stage I non-small cell lung cancer (NSCLC) overkill? A systematic review. <i>Radiotherapy and Oncology</i> , 2012, 105, 145-149.	0.6	89
206	A literature-based meta-analysis of clinical risk factors for development of radiation induced pneumonitis. <i>Acta Oncologica</i> , 2012, 51, 975-983.	1.8	190
207	Life years lost – comparing potentially fatal late complications after radiotherapy for pediatric medulloblastoma on a common scale. <i>Cancer</i> , 2012, 118, 5432-5440.	4.1	61
208	Methods for estimating the site of origin of locoregional recurrence in head and neck squamous cell carcinoma. <i>Strahlentherapie Und Onkologie</i> , 2012, 188, 671-676.	2.0	34
209	Lung Tumor Segmentation Using Electric Flow Lines for Graph Cuts. <i>Lecture Notes in Computer Science</i> , 2012, , 206-213.	1.3	4
210	MO-A-BRCD-01: Unsettled Issues in the Radiobiology of Emergent Technology: Hypofractionation and PET-Guided Treatment Planning. <i>Medical Physics</i> , 2012, 39, 3858-3858.	3.0	0
211	Estimated radiation pneumonitis risk after photon versus proton therapy alone or combined with chemotherapy for lung cancer. <i>Acta Oncologica</i> , 2011, 50, 772-776.	1.8	25
212	Estimating Life Years Lost to Quantify the Potential Benefit for Pediatric Patients of Advanced Photon or Proton Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, S665.	0.8	0
213	Comparison of Methods to Analyze Pattern of Failure in Head and Neck Squamous Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, S540.	0.8	0
214	Characterization of positron emission tomography hypoxia tracer uptake and tissue oxygenation via electrochemical modeling. <i>Nuclear Medicine and Biology</i> , 2011, 38, 771-780.	0.6	49
215	Radiation dose response of normal lung assessed by Cone Beam CT – A potential tool for biologically adaptive radiation therapy. <i>Radiotherapy and Oncology</i> , 2011, 100, 351-355.	0.6	44
216	Meta-analysis of the $\hat{1}\pm/\hat{1}^2$ -ratio for Prostate Cancer in the Presence of an Overall Time Factor: Bad News, Good News or No News?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, S404.	0.8	1

#	ARTICLE	IF	CITATIONS
217	Randomized, Double-Blinded, Placebo-Controlled Crossover Trial of Treating Erectile Dysfunction with Sildenafil After Radiotherapy and Short-Term Androgen Deprivation Therapy: Results of RTOG 0215. <i>Journal of Sexual Medicine</i> , 2011, 8, 1228-1238.	0.6	46
218	Molecular Imaging-Based Dose Painting: A Novel Paradigm for Radiation Therapy Prescription. <i>Seminars in Radiation Oncology</i> , 2011, 21, 101-110.	2.2	252
219	Risk factors for radiation-induced hypothyroidism. <i>Cancer</i> , 2011, 117, 5250-5260.	4.1	87
220	Fractionation for Whole Breast Irradiation: An American Society for Radiation Oncology (ASTRO) Evidence-Based Guideline. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 59-68.	0.8	366
221	Hypofractionated Whole-Breast Radiotherapy for Women With Early Breast Cancer: Myths and Realities. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 1-9.	0.8	142
222	In Response to Dr. Williams. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 639-640.	0.8	2
223	A Prospective Phase III Randomized Trial of Hypofractionation Versus Conventional Fractionation in Patients With High-Risk Prostate Cancer: In Regard to Arcangeli C, et al. (<i>Int J Radiat Oncol Biol Phys</i>) Tj ETQq1 1 0.784314 rgBT /Over	0.8	314
224	Intensity-Modulated Radiotherapy Might Increase Pneumonitis Risk Relative to Three-Dimensional Conformal Radiotherapy in Patients Receiving Combined Chemotherapy and Radiotherapy: A Modeling Study of Dose Dumping. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 893-899.	0.8	32
225	Radiobiological Aspects of Brachytherapy in the Era of 3-Dimensional Imaging. , 2011, , 131-142.		2
226	Evidence-Based Head and Neck Oncology: Principles and Pitfalls. , 2011, , 317-325.		0
227	WE-E-BRA-03: Therapy Symposium: A Clinician's View of Quantec. <i>Medical Physics</i> , 2011, 38, 3815-3816.	3.0	1
228	TU-A-BRC-04: Quantifying the Predictive Power of Multiparametric PET Imaging in a Prospective Veterinary Dose Escalation Trial through Voxel Regression. <i>Medical Physics</i> , 2011, 38, 3742-3742.	3.0	0
229	WE-E-BRA-02: Methodological Issues and Key Results in the QUANTEC 2010 Review of Radiation-Induced Normal Tissue Toxicity. <i>Medical Physics</i> , 2011, 38, 3815-3815.	3.0	0
230	Incidence of rib fractures after stereotactic body radiotherapy for peripheral lung lesions: clinical experience and dose response estimation. <i>Journal of Radiosurgery and SBRT</i> , 2011, 1, 155-161.	0.2	0
231	Comprehensive IMRT plus weekly cisplatin for advanced head and neck cancer: The University of Wisconsin experience. <i>Head and Neck</i> , 2010, 32, 599-606.	2.0	56
232	A New Method for Synthesizing Radiation Dose-Response Data From Multiple Trials Applied to Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 1066-1071.	0.8	37
233	Improving Normal Tissue Complication Probability Models: The Need to Adopt a "Data-Pooling" Culture. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, S151-S154.	0.8	101
234	On the Use of Hyperpolarized Helium MRI for Conformal Avoidance Lung Radiotherapy. <i>Medical Dosimetry</i> , 2010, 35, 297-303.	0.9	34

#	ARTICLE	IF	CITATIONS
235	Radiation Doseâ€“Volume Effects in the Lung. International Journal of Radiation Oncology Biology Physics, 2010, 76, S70-S76.	0.8	878
236	Use of Normal Tissue Complication Probability Models in the Clinic. International Journal of Radiation Oncology Biology Physics, 2010, 76, S10-S19.	0.8	1,376
237	The Lessons of QUANTEC: Recommendations for Reporting and Gathering Data on Doseâ€“Volume Dependencies of Treatment Outcome. International Journal of Radiation Oncology Biology Physics, 2010, 76, S155-S160.	0.8	171
238	Biomarkers and Surrogate Endpoints for Normal-Tissue Effects of Radiation Therapy: The Importance of Doseâ€“Volume Effects. International Journal of Radiation Oncology Biology Physics, 2010, 76, S145-S150.	0.8	69
239	Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): An Introduction to the Scientific Issues. International Journal of Radiation Oncology Biology Physics, 2010, 76, S3-S9.	0.8	879
240	Establishment of a Radiogenomics Consortium. International Journal of Radiation Oncology Biology Physics, 2010, 76, 1295-1296.	0.8	118
241	Reports of Unexpected Late Side Effects of Accelerated Partial Breast Irradiationâ€“Radiobiological Considerations. International Journal of Radiation Oncology Biology Physics, 2010, 77, 969-973.	0.8	68
242	Interim Results of a Phase I Risk-Stratified Dose Escalation Study using Hypofractionated Helical Tomotherapy for Non-small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2010, 78, S107-S108.	0.8	1
243	Radiotherapy With Concurrent Carbogen and Nicotinamide in Bladder Carcinoma. Journal of Clinical Oncology, 2010, 28, 4912-4918.	1.6	264
244	A systematic methodology review of phase I radiation dose escalation trials. Radiotherapy and Oncology, 2010, 95, 135-141.	0.6	21
245	Estimated risk of perihippocampal disease progression after hippocampal avoidance during whole-brain radiotherapy: Safety profile for RTOG 0933. Radiotherapy and Oncology, 2010, 95, 327-331.	0.6	166
246	Hypofractionated Radiotherapy for Breast Cancer. New England Journal of Medicine, 2010, 362, 1843-1844.	27.0	34
247	Methodologies for localizing loco-regional hypopharyngeal carcinoma recurrences in relation to FDG-PET positive and clinical radiation therapy target volumes. Acta OncolĂ³gica, 2010, 49, 984-990.	1.8	12
248	Hypofractionation does not increase radiation pneumonitis risk with modern conformal radiation delivery techniques. Acta OncolĂ³gica, 2010, 49, 1052-1057.	1.8	26
249	Feasibility of dose painting using volumetric modulated arc optimization and delivery. Acta OncolĂ³gica, 2010, 49, 964-971.	1.8	42
250	Fractionation Effects in Clinical Practice. , 2010, , 40-54.		1
251	MOâ€“204â€“01: Characterizing Uncertainties in Hypoxia Imagingâ€“Based Dose Painting Prescriptions. Medical Physics, 2010, 37, 3341-3341.	3.0	0
252	Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic Oncology. International Journal of Hyperthermia, 2009, 25, 323-334.	2.5	42

#	ARTICLE	IF	CITATIONS
253	The Impact of Hybrid PET-CT Scan on Overall Oncologic Management, with a Focus on Radiotherapy Planning: A Prospective, Blinded Study. <i>Technology in Cancer Research and Treatment</i> , 2009, 8, 149-158.	1.9	31
254	Molecular therapy in head and neck oncology. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 266-277.	27.6	86
255	Major Late Toxicities After Conformal Radiotherapy for Nasopharyngeal Carcinoma: Patient- and Treatment-Related Risk Factors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 73, 1121-1128.	0.8	95
256	On the sensitivity of IMRT dose optimization to the mathematical form of a biological imaging-based prescription function. <i>Physics in Medicine and Biology</i> , 2009, 54, 1483-1501.	3.0	57
257	Carbogen and nicotinamide in locally advanced bladder cancer: Early results of a phase-III randomized trial. <i>Radiotherapy and Oncology</i> , 2009, 91, 120-125.	0.6	43
258	Can we optimize chemo-radiation and surgery in locally advanced stage III non-small cell lung cancer based on evidence from randomized clinical trials? A hypothesis-generating study. <i>Radiotherapy and Oncology</i> , 2009, 93, 389-395.	0.6	14
259	Intensity-modulated x-ray (IMXT) versus proton (IMPT) therapy for theragnostic hypoxia-based dose painting. <i>Physics in Medicine and Biology</i> , 2009, 54, 1847-1847.	3.0	0
260	SU-FF-T-519: Potential for Increased Pneumonitis Risk with IMRT as Compared to 3D-CRT for Patients Receiving Adjuvant Chemotherapy: A Radiobiological Modeling Study. <i>Medical Physics</i> , 2009, 36, 2643-2643.	3.0	0
261	TH-D-304A-06: Comparison of Cu-ATSM and FMISO Uptake to Variations in Oxygen Tension. <i>Medical Physics</i> , 2009, 36, 2817-2817.	3.0	0
262	SU-FF-T-499: Quantitative Analysis of Normal Tissue Effects in the Clinic (QUANTEC): Limits and Recommendations for Use in Treatment Planning. <i>Medical Physics</i> , 2009, 36, 2638-2638.	3.0	0
263	Increased Oral Mucositis after IMRT versus Non-IMRT when Combined with Cetuximab and Cisplatin or Docetaxel for Head and Neck Cancer: Preliminary Results of RTOG 0234. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, S33.	0.8	15
264	Multiple biomarker tissue microarrays: bioinformatics and practical approaches. <i>Cancer and Metastasis Reviews</i> , 2008, 27, 481-494.	5.9	25
265	Primary Histology is Associated with Volumetric Response Following Whole Brain Radiation Therapy (WBRT) in Patients with Brain Metastases (BM). <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, S207.	0.8	0
266	HI-CHART: A Phase I/II Study on the Feasibility of High-Dose Continuous Hyperfractionated Accelerated Radiotherapy in Patients With Inoperable Non-Small-Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 132-138.	0.8	41
267	Relationship Between Neurocognitive Function and Quality of Life After Whole-Brain Radiotherapy in Patients With Brain Metastasis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 64-70.	0.8	259
268	Radiation Dose Prescription for Non-Small-Cell Lung Cancer According to Normal Tissue Dose Constraints: An In Silico Clinical Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 1103-1110.	0.8	66
269	Balancing on a Knife's Edge: Evidence-Based Medicine and the Marketing of Health Technology. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 12-14.	0.8	10
270	Pelvic Nodal Dose Escalation in Conjunction with Hypofractionated IMRT for High Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, S305.	0.8	1

#	ARTICLE	IF	CITATIONS
271	Single Institution Experience Treating Medically Inoperable Stage I Endometrial Cancer with High-dose Rate Intracavitary Brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, S370.	0.8	0
272	From Cellular to High-Throughput Predictive Assays in Radiation Oncology: Challenges and Opportunities. <i>Seminars in Radiation Oncology</i> , 2008, 18, 75-88.	2.2	45
273	Radiation Oncology Advances: An Introduction. <i>Cancer Treatment and Research</i> , 2008, 139, 1-4.	0.5	5
274	Randomized controlled trials in health technology assessment: Overkill or overdue?. <i>Radiotherapy and Oncology</i> , 2008, 86, 142-147.	0.6	93
275	The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. <i>Lancet, The</i> , 2008, 371, 1098-1107.	13.7	1,030
276	Radiation oncology health technology assessment – the best is the enemy of the good. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 563-563.	4.3	9
277	Dose Escalated, Hypofractionated Radiotherapy Using Helical Tomotherapy for Inoperable Non-Small Cell Lung Cancer: Preliminary Results of a Risk-Stratified Phase I Dose Escalation Study. <i>Technology in Cancer Research and Treatment</i> , 2008, 7, 441-447.	1.9	65
278	Intensity-modulated x-ray (IMXT) versus proton (IMPT) therapy for theragnostic hypoxia-based dose painting. <i>Physics in Medicine and Biology</i> , 2008, 53, 4153-4167.	3.0	69
279	Dose Painting and Theragnostic Imaging: Towards the Prescription, Planning and Delivery of Biologically Targeted Dose Distributions in External Beam Radiation Oncology. <i>Cancer Treatment and Research</i> , 2008, , 40-61.	0.5	11
280	WE-D-AUD A-03: Control Theory to Manage Spatial and Temporal Physiologic Changes. <i>Medical Physics</i> , 2008, 35, 2943-2943.	3.0	0
281	SU-DD-A1-04: Impact of Prescription Dose Gradient Discretization On Dose Painting. <i>Medical Physics</i> , 2008, 35, 2631-2631.	3.0	0
282	Dose painting and theragnostic imaging: towards the prescription, planning and delivery of biologically targeted dose distributions in external beam radiation oncology. <i>Cancer Treatment and Research</i> , 2008, 139, 41-62.	0.5	29
283	Surrogate End Points for Median Overall Survival in Metastatic Colorectal Cancer: Literature-Based Analysis From 39 Randomized Controlled Trials of First-Line Chemotherapy. <i>Journal of Clinical Oncology</i> , 2007, 25, 4562-4568.	1.6	217
284	Maximal neutropenia during chemotherapy and radiotherapy is significantly associated with the development of acute radiation-induced dysphagia in lung cancer patients. <i>Annals of Oncology</i> , 2007, 18, 909-916.	1.2	43
285	Evaluation of Early and Late Toxicities in Chemoradiation Trials. <i>Journal of Clinical Oncology</i> , 2007, 25, 4096-4103.	1.6	154
286	Optimization of tumour control probability in hypoxic tumours by radiation dose redistribution: a modelling study. <i>Physics in Medicine and Biology</i> , 2007, 52, 499-513.	3.0	77
287	Dose- and Time-Dependent Changes in Gene Expression in Human Glioma Cells after Low Radiation Doses. <i>Radiation Research</i> , 2007, 168, 199-208.	1.5	13
288	Literature-based analysis of preoperative chemoradiotherapy in oesophageal cancer: In response to Srinivas et al.. <i>Radiotherapy and Oncology</i> , 2007, 82, 107-108.	0.6	0

#	ARTICLE	IF	CITATIONS
289	Regression After Whole-Brain Radiation Therapy for Brain Metastases Correlates With Survival and Improved Neurocognitive Function. <i>Journal of Clinical Oncology</i> , 2007, 25, 1260-1266.	1.6	299
290	Late neurological complications after irradiation of malignant tumors of the testis. <i>Acta Oncologica</i> , 2007, 46, 497-503.	1.8	9
291	Design of clinical trials in radiation oncology: saving lives, not grays. , 2007, , 196-211.		2
292	PET-CT-Based Auto-Contouring in Non-Small-Cell Lung Cancer Correlates With Pathology and Reduces Interobserver Variability in the Delineation of the Primary Tumor and Involved Nodal Volumes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 771-778.	0.8	274
293	Hypoxia in Prostate Cancer: Correlation of BOLD-MRI With Pimonidazole Immunohistochemistry Initial Observations. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 1065-1071.	0.8	169
294	Radiotherapy Adapted to Spatial and Temporal Variability in Tumor Hypoxia. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 1496-1504.	0.8	70
295	Increasing Toxicity in Nonoperative Head and Neck Cancer Treatment: Investigations and Interventions. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, S79-S82.	0.8	26
296	Are We Influencing Outcome in Oropharynx Cancer With Intensity-Modulated Radiotherapy? An Inter-Era Comparison. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 1032-1041.	0.8	63
297	Whole Brain Radiotherapy With Hippocampal Avoidance and Simultaneously Integrated Brain Metastases Boost: A Planning Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 589-597.	0.8	176
298	A Prospective Study Comparing CT-Based to PET/CT-based Radiation Treatment Planning. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, S68-S69.	0.8	1
299	Dosimetric Evaluation of Helical IMRT, Traditional IMRT and 3-D Conformal Radiation for Inoperable Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, S632-S633.	0.8	2
300	Whole Brain Radiation Therapy With Hippocampal Avoidance and Simultaneously Integrated Brain Metastases Boost With Helical Tomotherapy: A Planning Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, S674-S675.	0.8	3
301	Single Institution Experience Treating 100 Vestibular Schwannomas With Fractionated Stereotactic Radiation Therapy or Stereotactic Radiosurgery. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, S121.	0.8	2
302	A general framework for quantifying the effects of DNA repair inhibitors on radiation sensitivity as a function of dose. <i>Theoretical Biology and Medical Modelling</i> , 2007, 4, 25.	2.1	6
303	Exploitable mechanisms for combining drugs with radiation: concepts, achievements and future directions. <i>Nature Clinical Practice Oncology</i> , 2007, 4, 172-180.	4.3	129
304	MO100J01: Dose Painting With Intensity Modulated Proton Therapy and Intensity Modulated X-Ray Therapy: A Comparison. <i>Medical Physics</i> , 2007, 34, 2522-2523.	3.0	5
305	MO100J08: Effect of a Biologically Based Prescription Function in IMRT Dose Optimization. <i>Medical Physics</i> , 2007, 34, 2524-2524.	3.0	1
306	TH-E-M100J-05: Early Assessment of Radiotherapy Efficacy with FLT-PET Imaging. <i>Medical Physics</i> , 2007, 34, 2650-2650.	3.0	0

#	ARTICLE	IF	CITATIONS
307	MOËDËBRAË01: Hypofractionated RT: Biological Basis and Clinical Application in the Prostate and Lung. Medical Physics, 2007, 34, 2524-2525.	3.0	0
308	Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial. Lancet Oncology, The, 2006, 7, 467-471.	10.7	520
309	Dose and fractionation regimens for breast cancer Æ“ Authors' reply. Lancet Oncology, The, 2006, 7, 619-620.	10.7	0
310	Influence of connective tissue diseases on the expression of radiation side effects: A systematic review. Radiotherapy and Oncology, 2006, 78, 123-130.	0.6	66
311	A modelling study of the potential influence of low dose hypersensitivity on radiation treatment planning. Radiotherapy and Oncology, 2006, 79, 115-121.	0.6	30
312	Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: Evidence of a radiation and chemotherapy dose response. Radiotherapy and Oncology, 2006, 78, 236-244.	0.6	154
313	70 Theragnostic imaging for radiation oncology: Dose-painting by numbers. Radiotherapy and Oncology, 2006, 78, S24.	0.6	0
314	76 Novel biology, new technology, same ol' clinical practice?. Radiotherapy and Oncology, 2006, 78, S26-S27.	0.6	0
315	189 The response of head and neck tumours to radiotherapy may be influenced by the interaction between cell proliferation and vascularization. Radiotherapy and Oncology, 2006, 78, S65-S66.	0.6	0
316	Pre-treatment proliferation and the outcome of conventional and accelerated radiotherapy. European Journal of Cancer, 2006, 42, 363-371.	2.8	15
317	Radiotherapy for head and neck cancer: latest developments and future perspectives. Current Opinion in Oncology, 2006, 18, 240-246.	2.4	15
318	Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology. Nature Reviews Cancer, 2006, 6, 702-713.	28.4	868
319	Integral radiation dose to normal structures with conformal external beam radiation. International Journal of Radiation Oncology Biology Physics, 2006, 64, 962-967.	0.8	139
320	An immunohistochemical assessment of hypoxia in prostate carcinoma using pimonidazole: Implications for radioresistance. International Journal of Radiation Oncology Biology Physics, 2006, 65, 91-99.	0.8	80
321	In response to Dr. PeÃ±agarÃceno. International Journal of Radiation Oncology Biology Physics, 2006, 65, 1274-1275.	0.8	1
322	80. International Journal of Radiation Oncology Biology Physics, 2006, 66, S47.	0.8	0
323	135. International Journal of Radiation Oncology Biology Physics, 2006, 66, S75-S76.	0.8	2
324	155. International Journal of Radiation Oncology Biology Physics, 2006, 66, S87.	0.8	3

#	ARTICLE	IF	CITATIONS
325	2387. International Journal of Radiation Oncology Biology Physics, 2006, 66, S425.	0.8	4
326	2396. International Journal of Radiation Oncology Biology Physics, 2006, 66, S429-S430.	0.8	0
327	Biologic Basis for Combining Drugs With Radiation. Seminars in Radiation Oncology, 2006, 16, 2-9.	2.2	167
328	Does a local bystander effect necessitate a revision of TCP models that are based on observed clinical data?. Acta OncolÅ³gica, 2006, 45, 406-411.	1.8	5
329	Comparison of CA-125 and Standard Definitions of Progression of Ovarian Cancer in the Intergroup Trial of Cisplatin and Paclitaxel Versus Cisplatin and Cyclophosphamide. Journal of Clinical Oncology, 2006, 24, 45-51.	1.6	94
330	ERRATUM. Acta OncolÅ³gica, 2006, 45, 110-110.	1.8	52
331	Endogenous Markers of Two Separate Hypoxia Response Pathways (hypoxia inducible factor 2 alpha) Tj ETQq1 1 0.784314 rgBT /Overlo Recruited in the CHART Randomized Trial. Journal of Clinical Oncology, 2006, 24, 727-735.	1.6	276
332	Time Between the First Day of Chemotherapy and the Last Day of Chest Radiation Is the Most Important Predictor of Survival in Limited-Disease Small-Cell Lung Cancer. Journal of Clinical Oncology, 2006, 24, 1057-1063.	1.6	301
333	Linear Accelerator Radiosurgery for Trigeminal Neuralgia. Neurosurgery, 2005, 57, 1193-1200.	1.1	47
334	Increased therapeutic ratio by 18FDG-PET CT planning in patients with clinical CT stage N2-N3M0 nonâ€“small-cell lung cancer: A modeling study. International Journal of Radiation Oncology Biology Physics, 2005, 61, 649-655.	0.8	151
335	Selective mediastinal node irradiation based on FDG-PET scan data in patients with nonâ€“small-cell lung cancer: A prospective clinical study. International Journal of Radiation Oncology Biology Physics, 2005, 62, 988-994.	0.8	202
336	Molecular Markers in the CHART Trial. International Journal of Radiation Oncology Biology Physics, 2005, 63, S72.	0.8	0
337	International Survey of 4D Dose-Prescriptions in IMRT for Head and Neck Squamous Cell Carcinoma: A Modeled Comparison of Expected Outcome. International Journal of Radiation Oncology Biology Physics, 2005, 63, S75.	0.8	0
338	Evolution in H&N IMRT Practice and Early Assessment of Outcome at a Single Academic Center. International Journal of Radiation Oncology Biology Physics, 2005, 63, S360-S361.	0.8	1
339	Post-Radiotherapy Neck Dissection Following Comprehensive H&N IMRT. International Journal of Radiation Oncology Biology Physics, 2005, 63, S378-S379.	0.8	0
340	Combining H&N IMRT with Weekly Cisplatin Chemotherapy: Early Toxicity and Outcome. International Journal of Radiation Oncology Biology Physics, 2005, 63, S383.	0.8	0
341	Integral Radiation Dose to Normal Structures with Conformal External Beam Radiation. International Journal of Radiation Oncology Biology Physics, 2005, 63, S559.	0.8	0
342	Steepness of the radiation dose-response curve for dose-per-fraction escalation keeping the number of fractions fixed. Acta OncolÅ³gica, 2005, 44, 825-828.	1.8	14

#	ARTICLE	IF	CITATIONS
343	Sequential or Concurrent Tamoxifen and Radiotherapy: To See or Not to See“That Is the Question!. Journal of Clinical Oncology, 2005, 23, 6266-6267.	1.6	7
344	Epidermal Growth Factor Receptor Expression in Pretreatment Biopsies From Head and Neck Squamous Cell Carcinoma As a Predictive Factor for a Benefit From Accelerated Radiation Therapy in a Randomized Controlled Trial. Journal of Clinical Oncology, 2005, 23, 5560-5567.	1.6	250
345	Adjuvant chemotherapy in colorectal cancer: A joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Acta OncolÅ³gica, 2005, 44, 904-912.	1.8	94
346	Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncology, The, 2005, 6, 112-117.	10.7	385
347	Overview of national guidelines for infrastructure and staffing of radiotherapy. ESTRO-QUARTS: Work package 1. Radiotherapy and Oncology, 2005, 75, 349.E1-349.E6.	0.6	148
348	Towards evidence-based guidelines for radiotherapy infrastructure and staffing needs in Europe: the ESTRO QUARTS project. Radiotherapy and Oncology, 2005, 75, 355-365.	0.6	202
349	Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial. Radiotherapy and Oncology, 2005, 75, 9-17.	0.6	452
350	The $\hat{\mu}/\hat{\sigma}^2$ ratio for prostate cancer: What is it, really?. Radiotherapy and Oncology, 2005, 76, 1-3.	0.6	149
351	Effects of radiotherapy planning with a dedicated combined PET-CT-simulator of patients with non-small cell lung cancer on dose limiting normal tissues and radiation dose-escalation: A planning study. Radiotherapy and Oncology, 2005, 77, 5-10.	0.6	135
352	Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiotherapy and Oncology, 2005, 77, 18-24.	0.6	867
353	Radiation therapy: Intensity modulated, image guided, biologically optimized and evidence based. Radiotherapy and Oncology, 2005, 77, 227-230.	0.6	58
354	O-146 Effects of radiotherapy planning with a dedicated combined PET-CT-simulator of patients with non-small cell lung cancer on dose limiting normal tissues and radiation dose-escalation: A planning study. Lung Cancer, 2005, 49, S50.	2.0	1
355	P-757 Omission of elective mediastinal node irradiation on basis ofCT-scans in patients with limited disease small cell lung cancer results in low isolated nodal failures: A phase II trial. Lung Cancer, 2005, 49, S318.	2.0	1
356	Prognostic survival scores in patients referred for cardiac transplantation. Journal of Heart and Lung Transplantation, 2005, 24, S110.	0.6	0
357	Simplified prognostic models for the assessment of ambulatory heart failure. Journal of Heart and Lung Transplantation, 2005, 24, S119.	0.6	0
358	Postoperative Treatment of Locally Advanced Head and Neck Cancers. , 2005, , 197-210.		2
359	MO-E-T-6E-02: Dose-Volume Modeling & Clinical Radiotherapy: The Art of Systematic Oversimplification. Medical Physics, 2005, 32, 2072-2072.	3.0	0
360	The Need for Adverse Effects Reporting Standards in Oncology Clinical Trials. Journal of Clinical Oncology, 2004, 22, 19-22.	1.6	143

#	ARTICLE	IF	CITATIONS
361	Molecular Marker Profiles Predict Locoregional Control of Head and Neck Squamous Cell Carcinoma in a Randomized Trial of Continuous Hyperfractionated Accelerated Radiotherapy. <i>Clinical Cancer Research</i> , 2004, 10, 3745-3754.	7.0	83
362	Pre-treatment Haemoglobin Concentration in Accelerated and Conventional Radiotherapy for Non-small Cell Lung Carcinoma. <i>Clinical Oncology</i> , 2004, 16, 58-62.	1.4	4
363	High-tech in radiation oncology: should there be a ceiling?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 58, 320-330.	0.8	70
364	Dosimetric correlates for acute esophagitis in patients treated with radiotherapy for lung carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 58, 1106-1113.	0.8	139
365	Investigation of relationship between change in locoregional control and change in overall survival in randomized controlled trials of modified radiotherapy in head-and-neck cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 60, 1405-1409.	0.8	31
366	Is sensitization with nicotinamide and carbogen dependent on nicotinamide concentration at the time of irradiation?. <i>International Journal of Radiation Biology</i> , 2004, 80, 499-506.	1.8	4
367	Molecular biomarkers and site of first recurrence after radiotherapy for head and neck cancer. <i>European Journal of Cancer</i> , 2004, 40, 2734-2741.	2.8	22
368	Molecular profiles as predictive marker for the effect of overall treatment time of radiotherapy in supraglottic larynx squamous cell carcinomas. <i>Radiotherapy and Oncology</i> , 2004, 72, 275-282.	0.6	46
369	Normal tissue effects: reporting and analysis. <i>Seminars in Radiation Oncology</i> , 2003, 13, 189-202.	2.2	127
370	Compliance to the prescribed dose and overall treatment time in five randomized clinical trials of altered fractionation in radiotherapy for head-and-neck carcinomas. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 55, 568-575.	0.8	50
371	Repopulation in radiation oncology: perspectives of clinical research. <i>International Journal of Radiation Biology</i> , 2003, 79, 581-585.	1.8	59
372	REPLY TO LETTER TO THE EDITOR, REGARDING OUR PAPER "INTERNATIONAL CONSENSUS ON PALLIATIVE RADIOTHERAPY ENDPOINTS FOR FUTURE CLINICAL TRIALS IN BONE METASTASES". <i>Radiotherapy and Oncology</i> , 2003, 67, 252.	0.6	0
373	Early Morbidity after Radiotherapy with or without Chemotherapy in Advanced Head and Neck Cancer. <i>Strahlentherapie Und Onkologie</i> , 2003, 179, 390-395.	2.0	47
374	A user's guide to evidence-based oncology. <i>European Journal of Cancer</i> , Supplement, 2003, 1, 77-91.	2.2	16
375	Assessment of morbidity in carcinoma of the cervix: a comparison of the LENT SOMA scales and the Franco-Italian glossary. <i>Radiotherapy and Oncology</i> , 2003, 69, 195-200.	0.6	35
376	Altered fractionation and combined radio-chemotherapy approaches. <i>European Journal of Cancer</i> , 2003, 39, 560-571.	2.8	86
377	How useful are observational reports in the evaluation of interventions for radiation morbidity?: an analysis of formalin therapy for late radiation proctitis. <i>Radiotherapy and Oncology</i> , 2002, 64, 291-295.	0.6	15
378	International consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. <i>Radiotherapy and Oncology</i> , 2002, 64, 275-280.	0.6	300

#	ARTICLE	IF	CITATIONS
379	Sensori-neural hearing loss after radiotherapy for nasopharyngeal carcinoma: individualized risk estimation. <i>Radiotherapy and Oncology</i> , 2002, 65, 9-16.	0.6	128
380	Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis. <i>NMR in Biomedicine</i> , 2002, 15, 132-142.	2.8	323
381	Deterministic rather than stochastic factors explain most of the variation in the expression of skin telangiectasia after radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 52, 198-204.	0.8	130
382	Accelerated hyperfractionation (AHF) compared to conventional fractionation (CF) in the postoperative radiotherapy of locally advanced head and neck cancer: influence of proliferation. <i>British Journal of Cancer</i> , 2002, 86, 517-523.	6.4	93
383	Chemotherapy and altered fractionation in head-and-neck cancer: in regard to Staar et al., <i>IJROBP</i> 2001;50:1161-1171. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 52, 1423.	0.8	3
384	Treatment-Related Morbidity and Hospital League Tables: Experience from a National Audit of Radiotherapy-Induced Morbidity in Cervical Carcinoma. <i>Clinical Oncology</i> , 2002, 14, 40-42.	1.4	5
385	From CHART to CHARTWEL in Non-small Cell Lung Cancer: Clinical Radiobiological Modelling of the Expected Change in Outcome. <i>Clinical Oncology</i> , 2002, 14, 372-381.	1.4	51
386	ACCELERATED RADIOTHERAPY VS. CHEMORADIATION IN NON-SMALL CELL LUNG CANCER: QUANTIFYING THE HAZARDS. <i>Radiotherapy and Oncology</i> , 2001, 58, 91-92.	0.6	4
387	Radiotherapy-related early morbidity in head and neck cancer: quantitative clinical radiobiology as deduced from the CHART trial. <i>Radiotherapy and Oncology</i> , 2001, 60, 123-135.	0.6	136
388	Late morbidity: the Damocles Sword of radiotherapy?. <i>Radiotherapy and Oncology</i> , 2001, 61, 219-221.	0.6	14
389	An evolutionary-game model of tumour-cell interactions: possible relevance to gene therapy. <i>European Journal of Cancer</i> , 2001, 37, 2116-2120.	2.8	62
390	Value of Epidermal Growth Factor Receptor, HER2, p53, and Steroid Receptors in Predicting the Efficacy of Tamoxifen in High-Risk Postmenopausal Breast Cancer Patients. <i>Journal of Clinical Oncology</i> , 2001, 19, 3376-3384.	1.6	109
391	ICTR 2000: individualizing cancer treatment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 49, 299.	0.8	1
392	The translational research chain: is it delivering the goods?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 49, 345-351.	0.8	33
393	bcl-2 expression in head and neck cancer: an enigmatic prognostic marker. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 49, 435-441.	0.8	49
394	Prognostic factor studies in oncology: osteosarcoma as a clinical example. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 49, 513-518.	0.8	29
395	Influence of plasma glutathione levels on radiation mucositis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 51, 460-464.	0.8	9
396	Radiotherapy for Bone Metastases. <i>Clinical Oncology</i> , 2001, 13, 88-90.	1.4	19

#	ARTICLE	IF	CITATIONS
397	Failure-specific prognostic factors after continuous hyperfractionated accelerated radiotherapy (CHART) or conventional radiotherapy in locally advanced non-small-cell lung cancer: A competing risks analysis. <i>British Journal of Cancer</i> , 2001, 85, 1113-1118.	6.4	12
398	Role of chance in familial aggregation of colorectal cancer. <i>British Journal of Cancer</i> , 2001, 84, 1084-1086.	6.4	6
399	Relationship between DNA double-strand breaks, cell killing, and fibrosis studied in confluent skin fibroblasts derived from breast cancer patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000, 46, 481-490.	0.8	62
400	Fractionated radiotherapy for metastatic bone pain: evidence-based medicine or...?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000, 46, 681-682.	0.8	21
401	National Audit of the Management and Outcome of Carcinoma of the Cervix Treated with Radiotherapy in 1993. <i>Clinical Oncology</i> , 2000, 12, 347-353.	1.4	70
402	Selection of Active Drugs for Ovarian Cancer Based on CA-125 and Standard Response Rates in Phase II Trials. <i>Journal of Clinical Oncology</i> , 2000, 18, 1733-1739.	1.6	90
403	The Influence of Delay in Diagnosis of Breast Cancer upon Outlook. <i>Clinical Risk</i> , 2000, 6, 4-6.	0.1	1
404	Lise Meitner and Niels Bohr?A Historical Note. <i>Acta OncolÅ³gica</i> , 2000, 39, 1002-1003.	1.8	6
405	Time Course of Radiological Lung Density Changes After Postmastectomy Radiotherapy. <i>Acta OncolÅ³gica</i> , 2000, 39, 181-187.	1.8	35
406	Morbidity Related to Axillary Irradiation in the Treatment of Breast Cancer. <i>Acta OncolÅ³gica</i> , 2000, 39, 337-347.	1.8	87
407	Clinical impact of dosimetry quality assurance programmes assessed by radiobiological modelling of data from the thermoluminescent dosimetry study of the European Organization for Research and Treatment of Cancer. <i>European Journal of Cancer</i> , 2000, 36, 615-620.	2.8	60
408	Fibroblast Differentiation in Subcutaneous Fibrosis after Postmastectomy Radiotherapy. <i>Acta OncolÅ³gica</i> , 2000, 39, 383-388.	1.8	40
409	UPDATED DATA FOR CHART IN NSCLC: FURTHER ANALYSES. <i>Radiotherapy and Oncology</i> , 2000, 55, 86-87.	0.6	24
410	Clinical radiation doses for spinal cord: the 1998 international questionnaire. <i>Radiotherapy and Oncology</i> , 2000, 55, 295-300.	0.6	32
411	Late functional response of mouse urinary bladder to fractionated X-irradiation. <i>International Journal of Radiation Biology</i> , 1999, 75, 1307-1315.	1.8	24
412	In vitro radiosensitivity of tumour cells and fibroblasts derived from head and neck carcinomas: mutual relationship and correlation with clinical data. <i>British Journal of Cancer</i> , 1999, 79, 1074-1084.	6.4	16
413	Chemotherapy and accelerated radiotherapy in head and neck carcinoma: the experience from four swiss centres. <i>European Journal of Cancer</i> , 1999, 35, S168.	2.8	0
414	Delay in diagnosis in breast cancer. <i>Lancet</i> , The, 1999, 353, 2155-2156.	13.7	9

#	ARTICLE	IF	CITATIONS
415	Carcinoma of the cervix and the use of hyperbaric oxygen with radiotherapy: a report of a randomised controlled trial. <i>Radiotherapy and Oncology</i> , 1999, 53, 93-98.	0.6	43
416	Repair halftimes estimated from observations of treatment-related morbidity after CHART or conventional radiotherapy in head and neck cancer. <i>Radiotherapy and Oncology</i> , 1999, 53, 219-226.	0.6	118
417	Use of tumour markers in monitoring the course of ovarian cancer. <i>Annals of Oncology</i> , 1999, 10, 21-27.	1.2	59
418	Prognostic Factors in Papillary and Follicular Thyroid Carcinomas. <i>Laryngoscope</i> , 1998, 108, 243-249.	2.0	37
419	Enzyme-linked immunosorbent assay of epidermal growth factor receptor in lung cancer: comparisons with immunohistochemistry, clinicopathological features and prognosis. <i>British Journal of Cancer</i> , 1998, 78, 96-99.	6.4	42
420	Increased risk of recurrence for patients with EGFR and HER-p185 positive tumours; when treated adjuvantly with tamoxifen for one year. <i>European Journal of Cancer</i> , 1998, 34, S81.	2.8	0
421	TUMOR CELL PROLIFERATION AND SURVIVAL IN PATIENTS WITH PROSTATE CANCER FOLLOWED EXPECTANTLY. <i>Journal of Urology</i> , 1998, 159, 1609-1614.	0.4	43
422	Radiosensitivity of normal fibroblasts from breast cancer patients assessed by the micronucleus and colony assays. <i>International Journal of Radiation Biology</i> , 1998, 73, 671-678.	1.8	23
423	Lack of predictive value of potential doubling time and iododeoxyuridine labelling index in radiotherapy of squamous cell carcinoma of the head and neck. <i>Radiotherapy and Oncology</i> , 1998, 46, 147-155.	0.6	31
424	Hyperfractionated radiotherapy in head and neck cancer: a second look at the clinical data. <i>Radiotherapy and Oncology</i> , 1998, 46, 127-130.	0.6	45
425	Towards evidence based radiation oncology: improving the design, analysis, and reporting of clinical outcome studies in radiotherapy. <i>Radiotherapy and Oncology</i> , 1998, 46, 5-18.	0.6	145
426	Randomized trial of single dose versus fractionated palliative radiotherapy of bone metastases. <i>Radiotherapy and Oncology</i> , 1998, 47, 233-240.	0.6	284
427	Differentiation state of skin fibroblast cultures versus risk of subcutaneous fibrosis after radiotherapy. <i>Radiotherapy and Oncology</i> , 1998, 47, 263-269.	0.6	56
428	Characterization and Radiosensitivity of Fibroblasts Derived from Squamous Cell Carcinomas of the Head and Neck, and the Surrounding Oral Mucosa. <i>Acta OncolÅ³gica</i> , 1998, 37, 697-700.	1.8	4
429	Clinical and Pharmacokinetic Risk Factors for High-dose Methotrexate-induced Toxicity in Children with Acute Lymphoblastic Leukemia: A Logistic Regression Analysis. <i>Acta OncolÅ³gica</i> , 1998, 37, 277-284.	1.8	85
430	Proliferative activity (MIB-1 index) is an independent prognostic parameter in patients with high-grade soft tissue sarcomas of subtypes other than malignant fibrous histiocytomas: a retrospective immunohistological study including 216 soft tissue sarcomas. <i>Histopathology</i> , 1998, 32, 536-546.	2.9	9
431	Re: Five-Day Oral Etoposide Treatment for Advanced Small-Cell Lung Cancer: Randomized Comparison With Intravenous Chemotherapy. <i>Journal of the National Cancer Institute</i> , 1997, 89, 1892-1893.	6.3	8
432	The effect of hypoxia and hyperoxia on nucleoside triphosphate/inorganic phosphate, pO ₂ and radiation response in an experimental tumour model. <i>British Journal of Cancer</i> , 1997, 76, 1432-1439.	6.4	16

#	ARTICLE	IF	CITATIONS
433	Progression rate of radiation damage to the mouse kidney: a quantitative analysis of experimental data using a simple mathematical model of the nephron. <i>International Journal of Radiation Biology</i> , 1997, 72, 461-473.	1.8	8
434	Quantifying the position and steepness of radiation dose-response curves. <i>International Journal of Radiation Biology</i> , 1997, 71, 531-542.	1.8	142
435	Potential clinical impact of normal-tissue intrinsic radiosensitivity testing. <i>Radiotherapy and Oncology</i> , 1997, 43, 121-131.	0.6	82
436	Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small-cell lung cancer. Aarhus Lung Cancer Group.. <i>Journal of Clinical Oncology</i> , 1997, 15, 3030-3037.	1.6	157
437	Steepness of the dose-response curve as a function of volume in an experimental tumor irradiated under ambient or hypoxic conditions. <i>International Journal of Radiation Oncology Biology Physics</i> , 1997, 39, 797-802.	0.8	20
438	Serum markers of bone metabolism in multiple myeloma: prognostic value of the carboxy-terminal telopeptide of type I collagen (ICTP). <i>British Journal of Haematology</i> , 1997, 96, 103-110.	2.5	53
439	Repair capacity and kinetics for human mucosa and epithelial tumors in the head and neck: clinical data on the effect of changing the time interval between multiple fractions per day in radiotherapy. <i>Radiotherapy and Oncology</i> , 1996, 38, 89-101.	0.6	66
440	Relationship between the in vitro radiosensitivity of skin fibroblasts and the expression of subcutaneous fibrosis, telangiectasia, and skin erythema after radiotherapy. <i>Radiotherapy and Oncology</i> , 1996, 40, 101-109.	0.6	149
441	Repair capacity of mouse lung after total body irradiation alone or combined with cyclophosphamide. <i>Radiotherapy and Oncology</i> , 1996, 40, 249-257.	0.6	4
442	Prophylactic cranial irradiation in limited stage small cell lung cancer: Survival benefit in patients with favourable characteristics. <i>European Journal of Cancer</i> , 1996, 32, 772-778.	2.8	14
443	Repopulation in the SCCVII squamous cell carcinoma assessed by an in vivo-in vitro excision assay. <i>Radiotherapy and Oncology</i> , 1996, 39, 137-144.	0.6	16
444	Risk Factors for Central Nervous System Involvement in Non-Hodgkins-Lymphoma a multivariate analysis. <i>Acta OncolÅ³gica</i> , 1996, 35, 703-708.	1.8	84
445	Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group.. <i>Journal of Clinical Oncology</i> , 1996, 14, 1146-1155.	1.6	170
446	Quantitative assessment of radiation-induced lung changes by computerized optical densitometry of routine chest x-rays. <i>International Journal of Radiation Oncology Biology Physics</i> , 1996, 34, 421-427.	0.8	8
447	Histopathologic, stereologic, epidemiologic, and clinical parameters in the prognostic evaluation of squamous cell carcinoma of the oral cavity. , 1996, 18, 142-152.		63
448	Dose-response relationships for late radiation effects in the head and neck: Regarding the analysis of the RTOG 8313 trial, fu et al <i>IJROBP</i> 32:577â€“588; 1995. <i>International Journal of Radiation Oncology Biology Physics</i> , 1996, 34, 523-524.	0.8	9
449	Tumor volume and local control probability: Clinical data and radiobiological interpretations. <i>International Journal of Radiation Oncology Biology Physics</i> , 1996, 36, 247-251.	0.8	100
450	Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic Oncology. <i>International Journal of Hyperthermia</i> , 1996, 12, 3-20.	2.5	201

#	ARTICLE	IF	CITATIONS
451	Radiotherapy-Related Lung Fibrosis Enhanced by Tamoxifen. <i>Journal of the National Cancer Institute</i> , 1996, 88, 918-922.	6.3	257
452	A 100-Year Nordic Perspective On The Dose-Time Problem In Radiobiology. <i>Acta OncolÅ³gica</i> , 1995, 34, 1031-1040.	1.8	7
453	Prognostic Value of Pretreatment Factors in Patients with Locally Advanced Carcinoma of the Uterine Cervix Treated by Radiotherapy Alone. <i>Acta OncolÅ³gica</i> , 1995, 34, 787-795.	1.8	48
454	Why actuarial estimates should be used in reporting late normal-tissue effects of cancer treatment â€ now!. <i>International Journal of Radiation Oncology Biology Physics</i> , 1995, 32, 1531-1534.	0.8	83
455	Time factor for tonsillar carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 1995, 33, 755-758.	0.8	13
456	Actual versus ideal treatment time in radiotherapy for head and neck cancer: Catching up with the gaps. <i>International Journal of Radiation Oncology Biology Physics</i> , 1995, 31, 687-688.	0.8	6
457	Time Evolution of the Number of Functional Murine Eccrine Sweat Glands after Irradiation: A Quantitative Analysis of Experimental Data Using a Model of Proliferative and Functional Organization. <i>International Journal of Radiation Biology</i> , 1995, 67, 565-575.	1.8	9
458	Delay in the diagnosis of oral squamous cell carcinoma. <i>Clinical Otolaryngology</i> , 1995, 20, 21-25.	1.2	111
459	Plasma tetranectin and colorectal cancer. <i>European Journal of Cancer</i> , 1995, 31, 888-894.	2.8	21
460	Dose escalation, treatment protraction, and the steepness of the dose-response curve for squamous cell carcinoma of the head and neck. <i>Radiotherapy and Oncology</i> , 1995, 34, 82-83.	0.6	0
461	Hyperthermia in cancer treatment. <i>Lancet, The</i> , 1995, 345, 1635-1637.	13.7	1
462	Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. <i>Lancet, The</i> , 1995, 345, 540-543.	13.7	551
463	Selective assessment of in vitro radiosensitivity of tumour cells and fibroblasts from single tumour biopsies using immunocytochemical identification of colonies in the soft agar clonogenic assay. <i>Radiotherapy and Oncology</i> , 1995, 37, 87-99.	0.6	20
464	Clinical Radiobiology and Normal-Tissue Morbidity after Breast Cancer Treatment. <i>Advances in Radiation Biology</i> , 1994, , 25-51.	0.4	21
465	Evidence for a Positive Correlation between in Vitro Radiosensitivity of Normal Human Skin Fibroblasts and the Occurrence of Subcutaneous Fibrosis after Radiotherapy. <i>International Journal of Radiation Biology</i> , 1994, 66, 407-412.	1.8	120
466	Influence of sampling time on assessment of potential doubling time. <i>Cytometry</i> , 1994, 16, 144-151.	1.8	17
467	Early and late radiotherapeutic morbidity in 442 consecutive patients with locally advanced carcinoma of the uterine cervix. <i>International Journal of Radiation Oncology Biology Physics</i> , 1994, 29, 941-952.	0.8	109
468	Introduction. <i>Seminars in Radiation Oncology</i> , 1994, 4, 53-54.	2.2	3

#	ARTICLE	IF	CITATIONS
469	Patient-to-patient variability in the expression of radiation-induced normal tissue injury. <i>Seminars in Radiation Oncology</i> , 1994, 4, 68-80.	2.2	190
470	Radiobiological considerations in the design of clinical trials. <i>Radiotherapy and Oncology</i> , 1994, 32, 1-11.	0.6	107
471	A re-analysis of available dose-response and time-dose data in Hodgkin's disease. <i>Radiotherapy and Oncology</i> , 1994, 30, 227-230.	0.6	44
472	Prediction of radiotherapy response using SF2: Why it may work after all. <i>Radiotherapy and Oncology</i> , 1994, 31, 85-86.	0.6	9
473	Loss of Reirradiation Tolerance in the Kidney with Increasing Time after Single or Fractionated Partial Tolerance Doses. <i>International Journal of Radiation Biology</i> , 1994, 66, 169-179.	1.8	30
474	Measurement of Human Tumour Oxygenation Status by a Polarographic Needle Electrode: An analysis of inter- and intratumour heterogeneity. <i>Acta OncolÅ³gica</i> , 1994, 33, 383-389.	1.8	177
475	Continuous or Split-Course Combined External and Intracavitary Radiotherapy of Locally Advanced Carcinoma of the Uterine Cervix. <i>Acta OncolÅ³gica</i> , 1994, 33, 547-555.	1.8	12
476	3-Methoxyazetidinium chloride. <i>Acta Crystallographica Section C: Crystal Structure Communications</i> , 1993, 49, 932-934.	0.4	2
477	Histological grade, DNA ploidy and mean nuclear volume as prognostic factors in prostatic cancer. <i>Apmis</i> , 1993, 101, 614-620.	2.0	12
478	A Mathematical Model for Cell Killing by Heat Applied to a C3H Mammary Carcinoma<i>in Vivo</i>. <i>International Journal of Radiation Biology</i> , 1993, 64, 113-117.	1.8	6
479	Modelling of serial carcinoembryonic antigen changes in colorectal cancer. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1993, 53, 751-755.	1.2	19
480	A Feasibility Study of Concomitant Boost Radiotherapy for Patients with Cancer of the Supraglottic Larynx. <i>Acta OncolÅ³gica</i> , 1993, 32, 637-640.	1.8	12
481	Reporting radiotherapeutic complications in patients with uterine cervical cancer. The importance of latency and classification system. <i>Radiotherapy and Oncology</i> , 1993, 28, 134-141.	0.6	34
482	Rates of local control, metastasis, and overall survival in patients with posterior uveal melanomas treated with ruthenium-106 plaques. <i>Radiotherapy and Oncology</i> , 1993, 28, 148-156.	0.6	43
483	Clinical correlations between late normal tissue endpoints after radiotherapy: Implications for predictive assays of radiosensitivity. <i>European Journal of Cancer</i> , 1993, 29, 1373-1376.	2.8	104
484	Short and Long Term Outcome in a Consecutive Series of 419 Patients with Acute Dialysis-Requiring Renal Failure. <i>Scandinavian Journal of Urology and Nephrology</i> , 1993, 27, 453-462.	1.4	36
485	Quantitative Clinical Radiobiology. <i>Acta OncolÅ³gica</i> , 1993, 32, 259-275.	1.8	55
486	Steepness of the Clinical Doseâ€“control Curve and Variation in the<i>in Vitro</i> Radiosensitivity of Head and Neck Squamous Cell Carcinoma. <i>International Journal of Radiation Biology</i> , 1992, 61, 417-423.	1.8	57

#	ARTICLE	IF	CITATIONS
487	Fractionation sensitivity and latency of late radiation injury to the mouse urinary bladder. <i>Radiotherapy and Oncology</i> , 1992, 25, 301-307.	0.6	19
488	Overall treatment time and tumor control dose for head and neck tumors: The dog leg revisited. <i>Radiotherapy and Oncology</i> , 1992, 25, 143-144.	0.6	22
489	Time to loco-regional recurrence after resection of Dukes' B and C colorectal cancer with or without adjuvant postoperative radiotherapy. A multivariate regression analysis. <i>British Journal of Cancer</i> , 1992, 65, 102-107.	6.4	97
490	Clinical evidence for tumor clonogen regeneration: interpretations of the data. <i>Radiotherapy and Oncology</i> , 1991, 22, 161-166.	0.6	153
491	Relationship between early and late normal-tissue injury after postmastectomy radiotherapy. <i>Radiotherapy and Oncology</i> , 1991, 20, 159-165.	0.6	172
492	Clinical radiobiology of squamous cell carcinoma of the oropharynx. <i>International Journal of Radiation Oncology Biology Physics</i> , 1991, 20, 1197-1206.	0.8	155
493	Direct Estimation of the Fraction of Hypoxic Cells from Tumour-control Data Obtained under Aerobic and Clamped Conditions. <i>International Journal of Radiation Biology</i> , 1991, 59, 1435-1440.	1.8	14
494	Phase III Trial of Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (Chop) Versus Cisplatin, Etoposide, Bleomycin and Prednisone (CisEBP) for the Treatment of Advanced Non-Hodgkin's Lymphoma of High Grade Malignancy. <i>Acta Oncologica</i> , 1990, 29, 995-999.	1.8	9
495	Cytotoxic effect of misonidazole and cyclophosphamide on aerobic and hypoxic cells in a C3H mammary carcinoma in vivo. <i>British Journal of Cancer</i> , 1990, 61, 61-64.	6.4	17
496	New Options in Direct Analysis of Dose-response Data. <i>International Journal of Radiation Biology</i> , 1990, 57, 221-225.	1.8	28
497	Does Variation in the <i>in Vitro</i> Cellular Radiosensitivity Explain the Shallow Clinical Dose-control Curve for Malignant Melanoma?. <i>International Journal of Radiation Biology</i> , 1990, 57, 117-126.	1.8	51
498	Fractionation sensitivity and latency of telangiectasia after postmastectomy radiotherapy: a graded-response analysis. <i>Radiotherapy and Oncology</i> , 1990, 18, 95-106.	0.6	58
499	Blood transfusion and prognosis in Dukes' B and C colorectal cancer. <i>European Journal of Cancer & Clinical Oncology</i> , 1990, 26, 457-463.	0.7	34
500	Time-dose factors in radiotherapy: a review of the human data. <i>Radiotherapy and Oncology</i> , 1990, 19, 219-235.	0.6	389
501	Are the results of the St Thomas' trial of post-mastectomy radiotherapy inconsistent with the predictions from the linear-quadratic model?. <i>British Journal of Radiology</i> , 1989, 62, 633-634.	2.2	8
502	Density changes at the proximal tibia after medial meniscectomy. <i>Journal of Orthopaedic Research</i> , 1989, 7, 744-753.	2.3	37
503	Fractionation sensitivity of a functional endpoint: impaired shoulder movement after post-mastectomy radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 1989, 17, 531-537.	0.8	91
504	Misonidazole combined with radiotherapy in the treatment of carcinoma of the uterine cervix. <i>International Journal of Radiation Oncology Biology Physics</i> , 1989, 16, 1069-1072.	0.8	55

#	ARTICLE	IF	CITATIONS
505	Predictors of hormone response for patients with ER-unknown breast tumours. British Journal of Cancer, 1989, 59, 421-425.	6.4	2
506	Incidence and latency of radiation reactions. Radiotherapy and Oncology, 1989, 14, 261-262.	0.6	17
507	Latent-time estimation for late cutaneous and subcutaneous radiation reactions in a single-follow-up clinical study. Radiotherapy and Oncology, 1989, 15, 267-274.	0.6	196
508	The predictive value of quantitative computed tomography for vertebral body compressive strength and ash density. Bone, 1989, 10, 465-470.	2.9	141
509	Clinical radiobiology of malignant melanoma. Radiotherapy and Oncology, 1989, 16, 169-182.	0.6	216
510	X-ray quantitative computed tomography: The relations to physical properties of proximal tibial trabecular bone specimens. Journal of Biomechanics, 1989, 22, 837-844.	2.1	106
511	Fractionation Parameters for Human Tissues and Tumors. International Journal of Radiation Biology, 1989, 56, 701-710.	1.8	111
512	Direct Estimation of Latent Time for Radiation Injury in Late-responding Normal Tissues: Gut, Lung, and Spinal Cord. International Journal of Radiation Biology, 1989, 55, 27-43.	1.8	77
513	Early and Late Normal-tissue Injury after Postmastectomy Radiotherapy Alone or Combined with Chemotherapy. International Journal of Radiation Biology, 1989, 56, 711-715.	1.8	76
514	Prognostic factors in osteosarcomas. A regression analysis. Cancer, 1988, 62, 194-202.	4.1	74
515	A regression analysis of prognostic factors after resection of Dukes' B and C carcinoma of the rectum and rectosigmoid. Does post-operative radiotherapy change the prognosis?. British Journal of Cancer, 1988, 58, 195-201.	6.4	56
516	Remodeling of the tibial plateau after knee replacement: CT bone densitometry. Acta Orthopaedica, 1988, 59, 567-573.	1.4	30
517	Relationship between radioligand binding assay, immunoenzyme assay and immunohistochemical assay for estrogen receptors in human breast cancer and association with tumor differentiation. European Journal of Cancer & Clinical Oncology, 1988, 24, 377-384.	0.7	30
518	Some Methodological Problems in Estimating Radiobiological Parameters from Clinical Data—Alpha/beta Ratios and Electron RBE for Cutaneous Reactions in Patients Treated with Postmastectomy Radiotherapy. Acta Oncologica, 1988, 27, 105-116.	1.8	69
519	Mechanical strength of tibial trabecular bone evaluated by X-ray computed tomography. Journal of Biomechanics, 1987, 20, 743-752.	2.1	69
520	The value of the NSD formula in equation of acute and late radiation complications in normal tissue following 2 and 5 fractions per week in breast cancer patients treated with postmastectomy irradiation. Radiotherapy and Oncology, 1987, 9, 1-11.	0.6	121
521	Remodelling of Trabecular Bone at the Proximal Tibia after Total Knee Replacement. A CT-Scan Study. Engineering in Medicine, 1986, 15, 89-93.	0.6	3
522	Evaluation of bladder tumor volume and CT number during radiotherapy: a comment on the paper by Swank-Bordewijk and van Kleffens. International Journal of Radiation Oncology Biology Physics, 1985, 11, 1228-1229.	0.8	4

#	ARTICLE	IF	CITATIONS
523	Isotherm mapping in hyperthermia using subtraction X-ray computed tomography. Radiotherapy and Oncology, 1984, 2, 255-260.	0.6	15
524	Small Cell Anaplastic Carcinoma of the Lung the Aarhus Experience 1976â€“1981. Acta Radiologica Oncology, 1984, 23, 153-158.	0.5	1
525	Impact of CT-Based Treatment Planning on Radiation Therapy of Carcinoma of the Bladder. Acta Radiologica Oncology, 1984, 23, 199-203.	0.5	5
526	Evaluation of the spatial resolution of a CT scanner by direct analysis of the edge response function. Medical Physics, 1983, 10, 579-581.	3.0	48
527	Experimental investigation of doubly excited states in Be II. Physical Review A, 1982, 26, 2639-2642.	2.5	19
528	New identifications of doubly excited quartet states in Be II. Journal of Physics B: Atomic and Molecular Physics, 1982, 15, L71-L74.	1.6	18
529	Lifetime measurements in singly ionized erbium using fast-beam laser-modulation spectroscopy. Journal of the Optical Society of America, 1982, 72, 1210.	1.2	17
530	Problems related to lifetime measurements in complex atoms using beam-foil and fast-beam/laser spectroscopy. Nuclear Instruments & Methods in Physics Research, 1982, 202, 139-145.	0.9	16
531	Spectroscopy of the uranium ion using collinear fast-beamâ€™cw-dye-laser modulation spectroscopy. Transition energies and excited-state lifetimes. Physical Review A, 1981, 24, 2523-2531.	2.5	31
532	Doubly excited quartet states in Be II. Journal of Physics B: Atomic and Molecular Physics, 1981, 14, 3435-3443.	1.6	27
533	Doubly Excited States in Be III. Physica Scripta, 1980, 22, 119-122.	2.5	47